UNITY cuts lead program after clinical trial fail

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Company to focus on ophthalmologic and neurologic programs as Phase 2 knee osteoarthritis clinical study fails to meet primary endpoint.

Senolytic therapy developer UNITY Biotechnology has announced the 12-week results from its Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in 183 patients with moderate-to-severe painful osteoarthritis of the knee. The study found no statistically significant difference in pain reduction between the use of UBX0101 and a placebo.

Longevity.Technology: Dang it. UNITY’s lead candidate drug, UBX0101, is a uniquely senolytic small molecule inhibitor of protein interaction. Disruption of this protein interaction triggers the destruction of senescent cells. So although this news relates to knee OA, it has relevance to the wider rejuvenation market. UNITY is also developing senolytic candidates for a variety of other age-related diseases.

UNITY said it “does not anticipate progressing UBX0101 into pivotal studies” and will focus instead on its ongoing ophthalmologic and neurologic disease programs. The company is evaluating compounds for the potential treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy.


 

“While these are not the results we had hoped for, the evidence that senescent cells contribute to diseases of aging remains compelling.”

 


 

“While we are disappointed in the outcome of the 12-week results of the Phase 2 study of UBX0101, I would like to acknowledge our team’s hard work and commitment to executing a robust study that has provided clear results,” said UNITY’s chief medical officer Jamie Dananberg.

The company’s stock fell 48% on today’s announcement, although setbacks such as this are not uncommon in the longevity sector, particularly among publicly traded companies such as UNITY and resTORbio, which are more susceptible to investor reaction.

“Developing novel treatments that selectively eliminate or modulate senescent cells is at the heart of what we do, and we have generated valuable data that will enable us to learn from this study and inform future studies in diseases of aging,” said UNITY CEO Anirvan Ghosh. “While these are not the results we had hoped for, the evidence that senescent cells contribute to diseases of aging remains compelling, and we are excited to advance UBX1325 for retinal diseases, which inhibits Bcl-xL, a distinct senolytic target.”

“Diabetic macular edema and diabetic retinopathy are attractive not only because of the strength of underlying biology, but also because of the sensitive, quantitative, and objective clinical assessments available,” added Ghosh. “The burden of senescent cells in various diseases of aging is increasingly evident, which together with our research gives us great conviction in our science and the future of our pipeline.”

Keep it up guys: only the brave etc.

Image credit: SlyzyyPexels

 

1 COMMENT

Comments are closed.

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...

A new approach to reversing tissue aging

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale...

Ovarian aging – your questions answered

Ovarian longevity and the significance of ovarian aging is poorly understood – our video aims to change that. Join our Scientific Editor Daragh Campbell as...

Learning lessons from clinical trial failure

Metabesity 2021: Joan Mannick talks longevity scientific breakthroughs, healthspan endpoints, her new role at Life Biosciences, and what can be learned from resTORbio’s clinical...